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encephalopathy 36.7% (33/90), lungs infection and
abdominal infection 17.8% (16/90), hepatorenal syndrome
23.3% (21/90), as well as alimentary tract hemorrhage
16.7% (15/90). 63 patients totally underwent plasma
pheresis, continuous hemoﬁltration and Molecular Absorbent
Recirculating System (MARS) therapy 76 sessions. HBV active
replication (HBVDNA positive) occurred in 78.9% of the
patients (71/90). 15 patients died within 30 days after
Ltx, and the perioperative mortality is 16.7%. Leading
post-Ltx complications were lungs infection 41.1% (37/90).
There were no primary liver nonfunction and blood vessel
complications in all the patients. Biliary complication
accounts for 12.2% (11/90).One-year survival is 76.1%
(54/71). Lamivudine combined HBIG were used to prevent
HBV recurrence, and there was no HBV graft reinfection and
hepatitis B recurrence during a mean 23-month follow up
period.
Conclusion: Acute on chronic hepatitis B patients
waiting for Ltx are generally with severe damaged liver
function, multiple-organ impairment and inner environment
derangement Therefore much should be done to improve
organ function so that better inner environment can be
obtained before Ltx. While during Surgery, attention should
be paid in the maintenance of coagulability and urine
output and in the shrinking of operation time. Attention
should also be paid to the intensive care of liver, lung
and kidney functions, the appropriate living graft volume,
the individual use of immunsuppresive agent and the
effective prophylaxis for acute lungs injury and secondary
infections post-operatively. With sufﬁcient efforts in all the
aspects listed above, acute on chronic hepatitis B patients
underwent Ltx could expect a satisfactory clinical outcome
and a better quality of life.
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Objective: To compare the long-term survivals of
orthotropic liver transplantation (OLT) in patient of HCC
within different selection criteria and analyze the risk
factors of tumor recurrence after liver transplantation.
Methods: OLT was performed on 103 patients with HCC at
Department of surgery of Beijing You-An hospital between
April 2004 and March 2008. The data were retrospectively
analyzed with regard to the response to OLT and survival.
The patients are divided into three group according to the
characteristics of tumor: group A (within Milan criteria),
group B (extra Milan criteria within UCSF criteria) and
group C (beyond UCSF criteria). Accumulative survival
rate and tumor-free Survivals were compared among three
groups.
Result: 1-, 2-, 3-year accumulative survival rate of 103
patients were 84.0%, 70.5% and 60.2%, which were 93.4%,
83.8%, 73.2% in group A (n = 50), 93.3%, 79.4%, 66.2%
in group B (n = 17) and 67.0%, 45.5%, 34.1% in group C
(n = 36) respectively. There is no difference in long-term
survival rate between group A and group B (P = 0.631),
while signiﬁcant difference between group A and group C
(P = 0.001) or group B and group C (P = 0.045).
Conclusion: HCC fulﬁlling Milan criteria is best indicated
for liver transplantation, and satisﬁed outcomes can be
achieved for the HCC recipients exceeding Milan criteria
but within UCSF criteria as well. Prognostic risk factors are
tumor staging and microvascular invasion of tumor.
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Background: Previous results have demonstrated that
HBeAg loss and seroconversion rates on ADV therapy were
signiﬁcantly correlated with baseline ALT levels. We present
predictors of long-term treatment outcomes, based on
both baseline ALT and HBV levels to help optimise patient
management.
Methods: Retrospective multivariate analyses assessed
the effects in a sub-group of study subjects with
baseline ALT >2×ULN and HBVDNA 108 copies/mL on-
treatment outcomes at Week 208.
Results: Subjects with baseline ALT >2×ULN and HBVDNA
108 copies/mL (n = 44) showed superior outcomes
compared to other study subjects with the proportion
achieving HBVDNA 300 copies/mL (68.18% vs. 52.02%,
P= 0.041), HBeAg loss (59.09% vs. 40.87%, P= 0.020), and
HBeAg seroconversion (38.64% vs. 23.80%, P= 0.031).
In subjects with baseline ALT >2×ULN and HBVDNA 108
copies/mL, and detextable HBVDNA at Week 208 ADV-
associated mutations were seen in 3.92% compared to 10.4%
in other subjects.
Conclusion: High baseline ALT and low baseline HBVDNA
were predictive of 4-years treatment outcomes in HBeAg-
Positive patients. Long-term outcomes were signiﬁcantly
better in HBeAg-Positive patients with baseline ALT >2×ULN
and HBVDNA 108 copies/mL.
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Background: Long-term antiviral therapy is the most
common approach in the treatment of CHB. Prediction
of long-term treatment outcomes based on early virologic
response may help optimize patient management.
Methods: 240 HBeAg positive CHB subjects received ADV
(adefovir dipivoxil 10mg) treatment for 208 weeks. The
effects of HBVDNA levels at Week 40 and outcomes at Week
208 were assessed by multivariate analyses.
Results: Subjects were grouped by HBVDNA at week 40:
105 and >105 copies/mL (table).
HBV DNA at Week 40
105 >105 P value
DNA undetectablea 72.87% 12.50% <0.001
HBeAg loss 55.04% 10.94% <0.001
HBeAg seroconversion 31.01% 4.69% <0.001
ALT normalization 85.27% 59.38% <0.001
ADV Mutation 10.08% 21.88% 0.026
a
300 copies/mL.
Conclusion: Low HBVDNA at Week 40 was predictive
of 4-year treatment outcomes in HBeAg-Positive chronic
